As global precision medicine advances rapidly, the development of innovative therapies for neurodegenerative diseases is reaching a historic turning point. We are proud to announce that Dr. Hung-Kai Kevin Chen, Founder and Chairman of Elixiron Immunotherapeutics, has been invited to attend the BIO Asia-Taiwan 2026 Special Forum. He will deliver a featured keynote presentation at Special Forum-3: Transforming Dementia Prevention and Control Models.
Co-organized by the Foundation of Medical Professionals Alliance in Taiwan (FMPAT) and other prominent organizations, this forum series brings together heavyweight leaders across government, academia, and industry, including Dr. Shih Chung-Liang (Minister of Health and Welfare, Taiwan) and Dr. Jung-Lung Hsu (President of the Taiwan Dementia Society). Representing Elixiron, Chairman Chen will share the stage with leading companies in the field of dementia to decipher the latest industry dynamics in Alzheimer's disease prevention and early diagnosis.
Keynote Presentation Information
-
Forum Theme: Special Forum-3 | Transforming Dementia Prevention and Control Models
-
Time: Friday, July 17, 2026, 17:20 - 17:30
-
Presentation Title: The Breakthrough Moment: Enrupatinib Establishes Neuroinflammation as a Disease-Modifying Target in Alzheimer's Disease
Presentation Highlights During this special forum, Chairman Chen will provide an in-depth analysis of Elixiron’s highly anticipated core pipeline program—Enrupatinib (EI-1071). With the dawn of a new therapeutic era, there is an urgent market demand for "Disease-Modifying Therapies" that can effectively delay or even reverse the progression of Alzheimer's disease. Elixiron has successfully targeted the mechanism of neuroinflammation, achieving therapeutic effects through precise immune regulation. Dr. Chen will share the latest clinical development progress and breakthrough data of Enrupatinib, demonstrating how Elixiron is building a pivotal competitive moat in the global race for innovative Alzheimer's drugs.
We cordially invite biotech professionals, investors, and partners to join us on-site to connect and witness the exciting results of our next-generation Alzheimer's therapy!
-
Forum Duration: Friday, July 17, 2026, 16:20 - 17:35 (Total duration of Forum-3)
-
Venue: Room 403, TaiNEX 1 (No. 1, Jingmao 2nd Rd., Nangang Dist., Taipei)
About Elixiron Immunotherapeutics Elixiron Immunotherapeutics is dedicated to developing globally competitive, innovative immunotherapies, focusing on unmet medical needs in cancer, autoimmune diseases, and neurodegenerative disorders. Through active international business development and licensing, Elixiron aims to bring entirely new opportunities and hope to patients worldwide.
